Navitoclax - an overview | ScienceDirect Topics
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Signal Transduction and Targeted Therapy
Cancers | Free Full-Text | Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models | HTML
BCL-2 Inhibitor ABT-199 Monotherapy for High-Risk Relapsed/Refractory CLL or SLL | Research To Practice
Venetoclax - Wikipedia
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
![PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ec51f354d5a228645aef51832a6d296b927bd6b/7-Figure4-1.png "PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar")
PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar
Functional evaluation of Bcl2 and BAX mutations. (A) ABT-199 was unable... | Download Scientific Diagram
Imaging Cellular Distribution of Bcl Inhibitors Using Small Molecule Drug Conjugates
![PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fdf95a15ef1cbf1ab603cd15531b69fef7da162f/7-Figure5-1.png "PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar")
PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar
Frontiers | The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
Ibr-7 synergized with ABT-199 in NSCLC A549 cells by triggering... | Download Scientific Diagram
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA | Cell Death & Disease
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors | Haematologica
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
Practical Fragments: Second fragment-based drug approved
ABT-199 activates the intrinsic mitochondrial apoptosis pathway in... | Download Scientific Diagram
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Leukemia
Venetoclax (ABT-199) | ≥99%(HPLC) | Selleck | Bcl-2 inhibitor
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. - Abstract - Europe PMC
Updated Results of a Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia | Research To Practice
Model for ABT-199-resistance and PI3K-mTOR-mediated targeting of... | Download Scientific Diagram
Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2 | Personalized Medicine in Oncology
Venetoclax (ABT-199) | BCL-2 Inhibitor | MedChemExpress
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
